Literature DB >> 11589886

Management of conjunctival and corneal melanoma with surgical excision, amniotic membrane allograft, and topical chemotherapy.

C L Shields1, J A Shields, T Armstrong.   

Abstract

PURPOSE: To illustrate a novel method of management for extensive conjunctival and corneal melanoma.
METHODS: Interventional case report. A 40-year-old Caucasian woman presented with a large, diffuse conjunctival melanoma involving 6 clock hours of the limbus. The remaining bulbar conjunctiva and the entire corneal epithelium were affected by diffuse, flat melanosis.
RESULTS: The conjunctival melanoma was completely resected microsurgically in one piece without disrupting the tumor. The conjunctival melanosis was treated with double freeze-thaw cryotherapy. The extensive conjunctival defect, involving one-half of the bulbar conjunctiva, was reconstructed with an amniotic membrane allograft. The corneal melanosis was subsequently treated with topical mitomycin C eyedrops. At 8 months follow-up, the conjunctiva and the cornea were completely healed with resolution of all pigment and 20/20 visual acuity.
CONCLUSION: Preliminary evidence suggests that combined therapeutic approaches, consisting of extensive tumor removal, cryotherapy, amniotic membrane allograft, and topical mitomyin C, can be effective in the management of diffuse conjunctival and corneal melanoma arising from primary acquired melanosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11589886     DOI: 10.1016/s0002-9394(01)01085-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  14 in total

1.  Fresh frozen amniotic membrane for conjunctival reconstruction after excision of neoplastic and presumed neoplastic conjunctival lesions.

Authors:  U Agraval; P Rundle; I G Rennie; S Salvi
Journal:  Eye (Lond)       Date:  2017-02-17       Impact factor: 3.775

2.  Primary acquired melanosis of the conjunctiva: experience with 311 eyes.

Authors:  Jerry A Shields; Carol L Shields; Arman Mashayekhi; Brian P Marr; Raquel Benavides; Archana Thangappan; Laura Phan; Ralph C Eagle
Journal:  Trans Am Ophthalmol Soc       Date:  2007

Review 3.  Ophthalmic manifestations and histopathology of xeroderma pigmentosum: two clinicopathological cases and a review of the literature.

Authors:  Hema L Ramkumar; Brian P Brooks; Xiaoguang Cao; Deborah Tamura; John J Digiovanna; Kenneth H Kraemer; Chi-Chao Chan
Journal:  Surv Ophthalmol       Date:  2011 Jul-Aug       Impact factor: 6.048

4.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

5.  Amniotic membrane transplantation for reconstruction after excision of large ocular surface neoplasias.

Authors:  E M Espana; P Prabhasawat; M Grueterich; A Solomon; S C G Tseng
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

6.  Epiphora as a side effect of topical mitomycin C.

Authors:  E Dafgård Kopp; S Seregard
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

7.  Excision with corneoscleral lamellar keratoplasty and amniotic membrane transplantation of a corneal displaced recurrent conjunctival melanoma.

Authors:  Eun Chul Kim; Man Soo Kim; Nam Yeo Kang
Journal:  Korean J Ophthalmol       Date:  2012-09-24

8.  Topical treatment options for conjunctival neoplasms.

Authors:  Jonathan W Kim; David H Abramson
Journal:  Clin Ophthalmol       Date:  2008-09

9.  Long-term outcome of amniotic membrane transplantation combined with mitomycin C for conjunctival reconstruction after ocular surface squamous neoplasia excision.

Authors:  Kazuomi Hanada; Noriko Nishikawa; Naoyuki Miyokawa; Akitoshi Yoshida
Journal:  Int Ophthalmol       Date:  2016-04-09       Impact factor: 2.031

Review 10.  [Topical Mitomycin C as a therapy of conjunctival tumours].

Authors:  M Schallenberg; N Niederdräing; K-P Steuhl; D Meller
Journal:  Ophthalmologe       Date:  2008-08       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.